Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 6-17 years of age~* Documented history of hypertension as defined in National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004)~* Must be ≥ 21.0 kg and ≤ 100.0 kg at randomization~* Able to safely wash out previous antihypertensive therapy for 1-2 weeks~Exclusion Criteria:~* Body weight of \< 21 kg (45 lbs) or \> 100 kg (220 lbs)~* Inability to discontinue prior antihypertensive medication as required during the washout period~* Any clinically significant abnormalities or clinically noteworthy abnormal laboratory values~* Renal artery stenosis~* Current diagnosis of heart failure (NYHA Class II-IV)~* msSBP ≥ 25% above the 95th percentile for age, gender, and height at Visit 2~* Second or third degree heart block with or without a pacemaker~* Atrial fibrillation or atrial flutter at Visit 1, or potentially life threatening or any symptomatic arrhythmia during the 12 months prior to Visit 1~* Evidence of current symptomatic valvular disease~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren 2 mg/kg (Type: EXPERIMENTAL): Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
- Aliskiren 6 mg/kg (Type: EXPERIMENTAL): Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning

Based on this trial design, predict the completion outcome and termination type (if applicable).